A preclinical investigation ascertained the targeting effect of NK cell line YT with gene transfer of a CD33-specific immunoglobulin-based humanized chimeric T cell receptor (cIgTCR) to CD33 + AML cell lines [117]. Here, CD33 is linked to acute myeloid leukemia.